Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1845 1
1916 1
1921 1
1925 1
1926 1
1931 1
1933 2
1934 1
1938 1
1939 2
1940 1
1941 2
1942 3
1943 1
1945 8
1946 19
1947 8
1948 15
1949 19
1950 11
1951 11
1952 17
1953 16
1954 11
1955 11
1956 20
1957 12
1958 11
1959 9
1960 9
1961 15
1962 13
1963 13
1964 12
1965 12
1966 20
1967 23
1968 28
1969 29
1970 36
1971 47
1972 37
1973 43
1974 47
1975 57
1976 54
1977 62
1978 80
1979 76
1980 105
1981 98
1982 105
1983 102
1984 103
1985 124
1986 132
1987 139
1988 166
1989 205
1990 205
1991 207
1992 242
1993 258
1994 240
1995 271
1996 255
1997 255
1998 260
1999 250
2000 279
2001 299
2002 298
2003 301
2004 339
2005 383
2006 421
2007 432
2008 493
2009 528
2010 548
2011 617
2012 635
2013 620
2014 698
2015 705
2016 719
2017 741
2018 718
2019 780
2020 849
2021 861
2022 851
2023 802
2024 802
2025 297

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,936 results

Results by year

Filters applied: . Clear all
Page 1
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Jänne PA, et al. Among authors: johnson ml. N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35658005 Clinical Trial.
Editorial 6.4.
Kinloch S, Psomas C, Johnson M. Kinloch S, et al. Among authors: johnson m. J Virus Erad. 2020 Oct 24;6(4):100020. doi: 10.1016/j.jve.2020.100020. eCollection 2020 Nov. J Virus Erad. 2020. PMID: 33329899 Free PMC article. No abstract available.
Bile acid synthesis impedes tumor-specific T cell responses during liver cancer.
Varanasi SK, Chen D, Liu Y, Johnson MA, Miller CM, Ganguly S, Lande K, LaPorta MA, Hoffmann FA, Mann TH, Teneche MG, Casillas E, Mangalhara KC, Mathew V, Sun M, Jensen IJ, Farsakoglu Y, Chen T, Parisi B, Deota S, Havas A, Lee J, Chung HK, Schietinger A, Panda S, Williams AE, Farber DL, Dhar D, Adams PD, Feng GS, Shadel GS, Sundrud MS, Kaech SM. Varanasi SK, et al. Among authors: johnson ma. Science. 2025 Jan 10;387(6730):192-201. doi: 10.1126/science.adl4100. Epub 2025 Jan 9. Science. 2025. PMID: 39787217
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Cho BC, et al. Among authors: johnson ml. Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576957 Clinical Trial.
Research priorities in pediatric parenteral nutrition: a consensus and perspective from ESPGHAN/ESPEN/ESPR/CSPEN.
Johnson MJ, Lapillonne A, Bronsky J, Domellof M, Embleton N, Iacobelli S, Jochum F, Joosten K, Kolacek S, Mihatsch WA, Moltu SJ, Puntis JWL, Riskin A, Shamir R, Tabbers MM, Van Goudoever JB, Saenz de Pipaon M; ESPGHAN/ESPEN/ESPR/CSPEN Working Group on Pediatric Parenteral Nutrition. Johnson MJ, et al. Pediatr Res. 2022 Jul;92(1):61-70. doi: 10.1038/s41390-021-01670-9. Epub 2021 Sep 2. Pediatr Res. 2022. PMID: 34475525 Free PMC article. Review.
Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture.
Pourmal S, Truong ME, Johnson MC, Yang Y, Zhou L, Alegre K, Stowe IB, Gupta S, Chen PA, Zhang Y, Rohou A, Newton K, Kayagaki N, Dixit VM, Deshpande I. Pourmal S, et al. Among authors: johnson mc. Nature. 2025 Jan;637(8045):446-452. doi: 10.1038/s41586-024-08273-4. Epub 2024 Oct 30. Nature. 2025. PMID: 39476863 Free PMC article.
Pseudosubarachnoid hemorrhage.
Zubair AS, Johnson M, Gilmore EJ. Zubair AS, et al. Among authors: johnson m. Surg Neurol Int. 2022 Jan 29;13:32. doi: 10.25259/SNI_499_2021. eCollection 2022. Surg Neurol Int. 2022. PMID: 35242398 Free PMC article.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML. Peters S, et al. Among authors: johnson ml. J Thorac Oncol. 2025 Jan;20(1):76-93. doi: 10.1016/j.jtho.2024.09.1381. Epub 2024 Sep 5. J Thorac Oncol. 2025. PMID: 39243945 Free article. Clinical Trial.
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Chung CH, et al. Among authors: johnson m. Clin Cancer Res. 2022 Jun 1;28(11):2329-2338. doi: 10.1158/1078-0432.CCR-21-3849. Clin Cancer Res. 2022. PMID: 35344035 Free PMC article. Clinical Trial.
17,936 results
You have reached the last available page of results. Please see the User Guide for more information.